Media

Latest news

Press Releases

SEE ALL
August 06, 2026

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalyst Topline data from pivotal
August 03, 2026

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

ROCKVILLE, Md., Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and operational highlights.
July 18, 2026

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies: Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related

Presentations & Publications

SEE ALL
July 18, 2026

Subretinal Delivery of Investigational Sura-vec Gene Therapy for Neovascular Age-Related Macular Degeneration: Long-Term Follow-Up of Phase 1/2a Participants

Robert Avery, MD, California Retina Consultants
July 17, 2026

Suprachoroidal Delivery of Investigational Surabgene Lomparvovec (Sura-vec*, ABBV-RGX-314): Results in NPDR at 2.5 Years

David S. Boyer, MD, Retina-Vitreous Associates Medical Group
March 11, 2026

RGX-202, An Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy: Interim Phase I/II Clinical Data

Carolina Tesi-Rocha, M.D., Clinical Professor of Neuromuscular Medicine, Stanford Medicine Children’s Health